Hall Laurie J Trustee lowered its position in Danaher Co. (NYSE:DHR – Get Rating) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,514 shares of the conglomerate’s stock after selling 285 shares during the quarter. Danaher makes up approximately 2.2% of Hall Laurie J Trustee’s portfolio, making the stock its 11th biggest position. Hall Laurie J Trustee’s holdings in Danaher were worth $4,915,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of DHR. Arkadios Wealth Advisors grew its stake in Danaher by 0.9% during the 4th quarter. Arkadios Wealth Advisors now owns 4,176 shares of the conglomerate’s stock valued at $1,108,000 after purchasing an additional 37 shares in the last quarter. American National Bank boosted its stake in shares of Danaher by 31.9% during the 3rd quarter. American National Bank now owns 157 shares of the conglomerate’s stock valued at $41,000 after buying an additional 38 shares during the last quarter. Stonebridge Capital Advisors LLC grew its position in shares of Danaher by 9.7% during the third quarter. Stonebridge Capital Advisors LLC now owns 428 shares of the conglomerate’s stock worth $111,000 after buying an additional 38 shares in the last quarter. Rosenbaum Jay D. increased its stake in shares of Danaher by 1.1% in the second quarter. Rosenbaum Jay D. now owns 3,564 shares of the conglomerate’s stock worth $904,000 after buying an additional 40 shares during the last quarter. Finally, Sandy Cove Advisors LLC raised its holdings in Danaher by 0.7% in the third quarter. Sandy Cove Advisors LLC now owns 5,540 shares of the conglomerate’s stock valued at $1,431,000 after acquiring an additional 40 shares in the last quarter. 77.26% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Danaher
In related news, Director Raymond C. Stevens sold 8,410 shares of the stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $264.27, for a total value of $2,222,510.70. Following the completion of the transaction, the director now owns 8,394 shares in the company, valued at approximately $2,218,282.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.20% of the company’s stock.
Danaher Price Performance
Danaher (NYSE:DHR – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The conglomerate reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.46 by $0.41. Danaher had a return on equity of 17.97% and a net margin of 22.91%. The business had revenue of $8.37 billion during the quarter, compared to analyst estimates of $7.90 billion. During the same quarter in the prior year, the firm posted $2.69 earnings per share. The company’s revenue was up 2.7% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Co. will post 10.14 EPS for the current fiscal year.
Danaher Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be issued a $0.27 dividend. The ex-dividend date is Thursday, March 30th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.25. Danaher’s dividend payout ratio is currently 10.36%.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on DHR. Robert W. Baird cut their target price on shares of Danaher from $321.00 to $309.00 in a research note on Wednesday, January 25th. Deutsche Bank Aktiengesellschaft started coverage on Danaher in a report on Tuesday, December 13th. They set a “buy” rating and a $310.00 target price on the stock. StockNews.com assumed coverage on Danaher in a report on Thursday. They issued a “buy” rating for the company. Barclays lifted their price objective on shares of Danaher from $277.00 to $290.00 and gave the stock an “overweight” rating in a report on Tuesday, January 24th. Finally, Credit Suisse Group cut shares of Danaher from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $315.00 to $300.00 in a report on Thursday, January 5th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $310.29.
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Get Rating).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.